MAB5466
Anti-Bestrophin Antibody
Chemicon®, from mouse
Synonym(s):
Anti-Anti-ARB, Anti-Anti-BEST, Anti-Anti-BMD, Anti-Anti-Best1V1Delta2, Anti-Anti-RP50, Anti-Anti-TU15B, Anti-Anti-VMD2
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
monoclonal
species reactivity
monkey, pig, mouse, bovine, human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... BEST1(7439)
Specificity
Reacts with bestrophin.
Immunogen
Recombinant human bestrophin protein.
Application
Detect Bestrophin using this Anti-Bestrophin Antibody validated for use in WB, IH.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Western blot: 5 μg/mL of this antibody detected Bestrophin in bovine retina cell lysate.
Immunohistochemistry (Paraffin) Analysis: A 1:20 dilution from a representative lot detected Bestrophin in mouse retina tissue sections.
Optimal working dilutions must be determined by end user.
Immunohistochemistry (Paraffin) Analysis: A 1:20 dilution from a representative lot detected Bestrophin in mouse retina tissue sections.
Optimal working dilutions must be determined by end user.
Physical form
Format: Purified
Purified immunoglobulin. Liquid in PBS containing 0.08% sodium azide.
Storage and Stability
Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sandra Petrus-Reurer et al.
Stem cells translational medicine, 9(8), 936-953 (2020-04-23)
As pluripotent stem cell (PSC)-based reparative cell therapies are reaching the bedside, there is a growing need for the standardization of studies concerning safety of the derived products. Clinical trials using these promising strategies are in development, and treatment for
Biju B Thomas et al.
Frontiers in neuroscience, 15, 752958-752958 (2021-11-13)
End-stage age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are two major retinal degenerative (RD) conditions that result in irreversible vision loss. Permanent eye damage can also occur in battlefields or due to accidents. This suggests there is an unmet
Altered zinc homeostasis in a primary cell culture model of the retinal pigment epithelium.
??lvarez-Barrios, et al.
Frontiers in nutrition, 10, 1124987-1124987 (2023)
Teisha J Rowland et al.
Journal of tissue engineering and regenerative medicine, 7(8), 642-653 (2012-04-20)
A potential application of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) is the generation of retinal pigmented epithelium (RPE) to treat age-related macular degeneration (AMD), a common but incurable retinal disease. RPE cells derived from hESCs
Divya Sinha et al.
American journal of human genetics, 107(2), 278-292 (2020-07-25)
Dominantly inherited disorders are not typically considered to be therapeutic candidates for gene augmentation. Here, we utilized induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) to test the potential of gene augmentation to treat Best disease, a dominant macular dystrophy
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service